{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:52:16Z","timestamp":1732035136884},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":427,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Dermatol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1111\/ced.12385","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T02:52:39Z","timestamp":1404269559000},"page":"717-719","source":"Crossref","is-referenced-by-count":11,"title":["Multiple halo naevi associated with tocilizumab"],"prefix":"10.1093","volume":"39","author":[{"given":"K.","family":"Kuet","sequence":"first","affiliation":[{"name":"Department of Dermatology; Chapel Allerton Hospital; Leeds West Yorkshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Goodfield","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Chapel Allerton Hospital; Leeds West Yorkshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,7,1]]},"reference":[{"key":"10.1111\/ced.12385-BIB0001|ced12385-cit-0001","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"10.1111\/ced.12385-BIB0002|ced12385-cit-0002","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.cyto.2008.07.014","article-title":"Cytokines as a key component of cancer-related inflammation","volume":"43","author":"Germano","year":"2008","journal-title":"Cytokine"},{"key":"10.1111\/ced.12385-BIB0003|ced12385-cit-0003","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1034\/j.1600-0749.2002.1o049.x","article-title":"New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions","volume":"15","author":"Moretti","year":"2002","journal-title":"Pigment Cell Res"},{"key":"10.1111\/ced.12385-BIB0004|ced12385-cit-0004","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1468-3083.2011.04160.x","article-title":"Halo naevi with associated vitiligo-like depigmentations: pathogenetic hypothesis","volume":"26","author":"Geel","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/ced.12385-BIB0005|ced12385-cit-0005","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0190-9622(97)70181-6","article-title":"The immune response in halo naevi","volume":"37","author":"Zeff","year":"1997","journal-title":"Am Acad Dermatol"},{"key":"10.1111\/ced.12385-BIB0006|ced12385-cit-0006","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000111523","article-title":"Worsening alopecia areata and de novo occurrence of multiple halo naevi in a patient receiving infliximab","volume":"216","author":"Fabre","year":"2008","journal-title":"Dermatology"},{"key":"10.1111\/ced.12385-BIB0007|ced12385-cit-0007","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ad.2011.02.018","article-title":"Halo naevi associated with interferon beta-1a therapy","volume":"103","author":"Vera-Iglesias","year":"2012","journal-title":"Actas Dermosifiliogr"},{"key":"10.1111\/ced.12385-BIB0008|ced12385-cit-0008","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1468-3083.2009.03404.x","article-title":"Halo naevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient","volume":"24","author":"Fava","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/ced.12385-BIB0009|ced12385-cit-0009","first-page":"154","article-title":"Molecular mechanisms of action of Interleukin-6 (IL-6)","volume":"20","author":"Toumpanakis","year":"2007","journal-title":"Pneumon"},{"key":"10.1111\/ced.12385-BIB0010|ced12385-cit-0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/OARRR.S17118","article-title":"Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis","volume":"3","author":"Mihara","year":"2011","journal-title":"Open Access Rheumatol Res Rev"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fced.12385","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ced.12385\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:39:39Z","timestamp":1676385579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/39\/6\/717\/6620930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,1]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,8]]}},"URL":"https:\/\/doi.org\/10.1111\/ced.12385","relation":{},"ISSN":["0307-6938"],"issn-type":[{"value":"0307-6938","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7,1]]}}}